TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Treating younger patients with TAVR increases risk of death
Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely.
Cardiologist demand is on the rise—can hospitals keep up?
Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind.
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.
New data put a spotlight on troubling TAVR trends
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

TAVR safe for low-risk patients with bicuspid aortic valve disease

More research on long-term outcomes is still needed before TAVR can be recommended for such patients across the board.

October 12, 2020

Some high-risk patients died during the delay, the research team reported.

October 1, 2020

New study highlights the benefits of treating aortic stenosis, CAD with TAVR instead of surgery

Patients who received TAVR and PCI experienced lower rates of mortality and fewer major bleeding events than those treated with SAVR and CABG.

September 29, 2020

TAVR outcomes after 1 year much worse for patients with valvular AFib

The study focused on more than 1,400 TAVR patients treated from August 2007 to June 2018.

September 22, 2020

The unlikely relationship between TAVR and chronic kidney disease

“The findings of this study will influence shared decision-making between chronic kidney disease patients and the heart team,” one specialist observed.

September 15, 2020

Endocarditis after TAVR: Increasingly rare, but incredibly fatal

The authors examined data from more than 134,000 TAVR patients, noting that 65% of endocarditis infections occurred within one year after the procedure.

September 8, 2020

TAVR outcomes similar after conscious sedation and general anesthesia

The new research out of Germany suggests both strategies are safe and effective for patients.

August 21, 2020

How population density can influence TAVR utilization, patient outcomes

Patient access to TAVR centers is often limited in rural areas where resources are in short supply.

August 20, 2020

TAVR

Treating younger patients with TAVR increases risk of death

Cardiologist demand is on the rise—can hospitals keep up?

Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years

New data put a spotlight on troubling TAVR trends

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes